Loading…
Loading…
CRSP does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CRSP and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CRSP and 80,000+ other tickers.
See exactly how CRSP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CRSP and 80,000+ other tickers.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship…
Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,853,875 shares of the company's stock after selling 104,236 shares during the quarter. CRISPR
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are imminent. CASGEVY's efficacy and expanding market access, combined with a robust cash position, underpin a favorable risk/reward at current levels.
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.
CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.